按拟议的美英联合风险分层指南的进展期结直肠肿瘤风险
本研究纳入2570例结肠镜检查发现至少1枚腺瘤的患者,按腺瘤数量与组织学分为6组,比较3年时进展期结直肠肿瘤风险。结果显示≥5枚腺瘤且至少1枚进展期腺瘤组风险最高(9.6%),显著高于≥5枚非进展期腺瘤组(4.5%)和1至2枚腺瘤且至少1枚进展期腺瘤组(4.6%)。作者认为可对≥5枚腺瘤且至少1枚进展期腺瘤者建议比3年更密集的监测,对3至4枚非进展期腺瘤和≥5枚非进展期腺瘤者分别建议比3年和1年更宽松的监测。
要点
- ≥5枚腺瘤且至少1枚进展期腺瘤组3年进展期结直肠肿瘤风险为9.6%。
- ≥5枚非进展期腺瘤组风险为4.5%,与1至2枚腺瘤且至少1枚进展期腺瘤组(4.6%)无显著差异。
- 结肠镜检查时超过1枚进展期腺瘤是进展期结直肠肿瘤的独立危险因素。
核心结论
- 作者认为可对≥5枚腺瘤且至少1枚进展期腺瘤的患者建议比3年间隔更密集的监测。
- 作者认为可对3至4枚非进展期腺瘤和≥5枚非进展期腺瘤的患者分别建议比3年和1年间隔更宽松的监测。
研究设计与样本
- 研究纳入2570例在指数结肠镜检查时发现至少1枚腺瘤的患者。
- 患者分为6组:第1组为1至2枚非进展期腺瘤(non-AAs)且无≥10毫米、高级别上皮内瘤变或绒毛状腺瘤;第1A组为1至2枚腺瘤且至少1枚进展期腺瘤(AA);第2组为3至4枚非进展期腺瘤;第2A组为3至4枚腺瘤且至少1枚进展期腺瘤;第3组为≥5枚非进展期腺瘤;第3A组为≥5枚腺瘤且至少1枚进展期腺瘤。
- 比较6组在3年时进展期结直肠肿瘤(CRN)的风险。
主要发现
- 第3A组进展期结直肠肿瘤风险为9.6%,高于第3组的4.5%(P = .03)和第1A组的4.6%(P < .001)。
- 第3组进展期结直肠肿瘤风险为4.5%,与第1A组的4.6%(P = .91)和第2A组的6.8%(P = .25)均无显著差异。
- 第1组与第2组进展期结直肠肿瘤风险分别为1.7%与2.2%,无显著差异(P = .22)。
- 指数结肠镜检查时超过1枚进展期腺瘤是进展期结直肠肿瘤的独立危险因素。
临床怎么用
- 作者认为可对≥5枚腺瘤且至少1枚进展期腺瘤的患者建议比3年间隔更密集的监测。
- 作者认为可对3至4枚非进展期腺瘤的患者建议比3年间隔更宽松的监测。
- 作者认为可对≥5枚非进展期腺瘤的患者建议比1年间隔更宽松的监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The U.K. guidelines for risk stratification after colon polypectomy differ from the U.S. guidelines in 2 ways: the U.K. guidelines consider ≥5 adenomas as high risk and do not consider histology (villous or high-grade dysplasia) in the assessment. Thus, we aimed to investigate the risk of advanced colorectal neoplasm (CRN) by categorized risk groups, considering both ≥5 adenomas and histology. METHODS: A total of 2570 patients with ≥1 adenoma at index colonoscopy were included. The patients were divided into 6 groups: group 1, 1 to 2 non-advanced adenomas (non-AAs) ≥10 mm or high-grade dysplasia or villous adenoma; group 1A, 1 to 2 adenomas with ≥1 advanced adenoma (AA); group 2, 3 to 4 non-AAs; group 2A, 3 to 4 adenomas with ≥1 AA; group 3, ≥5 non-AAs; and group 3A, ≥5 adenomas with ≥1 AA. The risk of advanced CRN at 3 years was compared among the 6 groups. RESULTS: Group 3A showed a higher risk of advanced CRN (9.6%) than group 3 (4.5%; P = .03) and group 1A (4.6%; P < .001). The risk of advanced CRN in group 3 (4.5%) showed no difference compared with group 1A (4.6%; P = .91) or group 2A (6.8%; P = .25). There was no difference between group 1 and group 2 in the risk of advanced CRN (1.7% vs 2.2%; P = .22). More than 1 AA at index colonoscopy was an independent risk factor for advanced CRN. CONCLUSION: More-intensive surveillance than the 3-year interval for patients with ≥5 adenomas with ≥1 AA and less-intensive surveillance than the 3-year and 1-year intervals for those with 3 to 4 non-AAs and ≥5 non-AAs, respectively, might be suggested.
引用
- Park SK, Yang HJ, Jung YS, et al. Risk of advanced colorectal neoplasm by the proposed combined United States and United Kingdom risk stratification guidelines. Gastrointest Endosc. 2017. PMID: 28986265. doi:10.1016/j.gie.2017.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。